Impact of consolidation immunotherapy after definitive chemoradiotherapy in locally advanced esophageal squamous cell carcinoma: a real-world multicenter study

IF 5.6 2区 医学 Q2 IMMUNOLOGY
International immunopharmacology Pub Date : 2025-12-22 Epub Date: 2025-10-13 DOI:10.1016/j.intimp.2025.115666
Nuo Yu , Cheng Chen , Xiaomin Wang , Xiaolin Ge , Xiongtao Yang , Jiao Li , Guojie Feng , Ziyu Zheng , Lei Deng , Tao Zhang , Wenqing Wang , Wenyang Liu , Jianyang Wang , Qinfu Feng , Jima Lv , Zongmei Zhou , Zefen Xiao , Nan Bi , Yingying Jiang , Qin Xiao , Xin Wang
{"title":"Impact of consolidation immunotherapy after definitive chemoradiotherapy in locally advanced esophageal squamous cell carcinoma: a real-world multicenter study","authors":"Nuo Yu ,&nbsp;Cheng Chen ,&nbsp;Xiaomin Wang ,&nbsp;Xiaolin Ge ,&nbsp;Xiongtao Yang ,&nbsp;Jiao Li ,&nbsp;Guojie Feng ,&nbsp;Ziyu Zheng ,&nbsp;Lei Deng ,&nbsp;Tao Zhang ,&nbsp;Wenqing Wang ,&nbsp;Wenyang Liu ,&nbsp;Jianyang Wang ,&nbsp;Qinfu Feng ,&nbsp;Jima Lv ,&nbsp;Zongmei Zhou ,&nbsp;Zefen Xiao ,&nbsp;Nan Bi ,&nbsp;Yingying Jiang ,&nbsp;Qin Xiao ,&nbsp;Xin Wang","doi":"10.1016/j.intimp.2025.115666","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>To compare the efficacy of dCRT versus dCRT plus consolidation ICIs (dCRT + cICIs) in LA-ESCC and to evaluate the safety of dCRT + cICIs.</div></div><div><h3>Methods</h3><div>Patients with LA-ESCC who received dCRT or dCRT + cICIs were included. sIPTW adjusted for sex, age, clinical TNM stage, smoking, and alcohol consumption between the two groups. The study analyzed overall survival (OS) and progression-free survival (PFS) between the two groups, and evaluated immune-related adverse events (irAEs) within the dCRT + cICIs cohort.</div></div><div><h3>Results</h3><div>We retrospectively identified 176 ESCC patients, with 123 in the dCRT group and 53 in the dCRT + cICIs group. Pre-sIPTW analysis showed significantly improved OS in the dCRT + cICIs group (median, 46.4 vs. 20.9 months; <em>P</em> = 0.02). The dCRT + cICIs group had a better PFS than the dCRT group (median, 27.4 vs. 12.9 months; P = 0.02). After sIPTW, the OS was numerically better in the dCRT + cICIs group than in the dCRT group (median, 42.9 vs. 21.6 months; <em>P</em> = 0.1), with improvement in 1- and 2-year OS rates. There was no significant difference in PFS between dCRT + cICIs group and dCRT group (median, 23.0 vs. 13.0 months; <em>P</em> = 0.2), with numerically better 1- and 2-year PFS in the dCRT + cICIs group. In the dCRT + cICIs group, approximately 43.4 % of patients experienced irAEs, and grade 3–4 irAEs occurred in 13.2 % of patients. The most common was hypothyroidism in 11.3 % of patients.</div></div><div><h3>Conclusions</h3><div>Our preliminary findings suggested that consolidation immunotherapy following dCRT might trend toward prolonged OS and PFS in patients with LA-ESCC, and that irAEs are generally tolerated.</div></div>","PeriodicalId":13859,"journal":{"name":"International immunopharmacology","volume":"167 ","pages":"Article 115666"},"PeriodicalIF":5.6000,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International immunopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1567576925016571","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/13 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose

To compare the efficacy of dCRT versus dCRT plus consolidation ICIs (dCRT + cICIs) in LA-ESCC and to evaluate the safety of dCRT + cICIs.

Methods

Patients with LA-ESCC who received dCRT or dCRT + cICIs were included. sIPTW adjusted for sex, age, clinical TNM stage, smoking, and alcohol consumption between the two groups. The study analyzed overall survival (OS) and progression-free survival (PFS) between the two groups, and evaluated immune-related adverse events (irAEs) within the dCRT + cICIs cohort.

Results

We retrospectively identified 176 ESCC patients, with 123 in the dCRT group and 53 in the dCRT + cICIs group. Pre-sIPTW analysis showed significantly improved OS in the dCRT + cICIs group (median, 46.4 vs. 20.9 months; P = 0.02). The dCRT + cICIs group had a better PFS than the dCRT group (median, 27.4 vs. 12.9 months; P = 0.02). After sIPTW, the OS was numerically better in the dCRT + cICIs group than in the dCRT group (median, 42.9 vs. 21.6 months; P = 0.1), with improvement in 1- and 2-year OS rates. There was no significant difference in PFS between dCRT + cICIs group and dCRT group (median, 23.0 vs. 13.0 months; P = 0.2), with numerically better 1- and 2-year PFS in the dCRT + cICIs group. In the dCRT + cICIs group, approximately 43.4 % of patients experienced irAEs, and grade 3–4 irAEs occurred in 13.2 % of patients. The most common was hypothyroidism in 11.3 % of patients.

Conclusions

Our preliminary findings suggested that consolidation immunotherapy following dCRT might trend toward prolonged OS and PFS in patients with LA-ESCC, and that irAEs are generally tolerated.
局部晚期食管鳞状细胞癌放化疗后巩固免疫治疗的影响:一项真实的多中心研究。
目的:比较dCRT与dCRT +巩固性ICIs (dCRT + cICIs)治疗LA-ESCC的疗效,评价dCRT + cICIs的安全性。方法:纳入接受dCRT或dCRT + cICIs治疗的LA-ESCC患者。两组间的sIPTW校正了性别、年龄、临床TNM分期、吸烟和饮酒。该研究分析了两组之间的总生存期(OS)和无进展生存期(PFS),并评估了dCRT + cICIs队列中的免疫相关不良事件(irAEs)。结果:我们回顾性发现176例ESCC患者,其中123例为dCRT组,53例为dCRT + cICIs组。siptw前分析显示,dCRT + cICIs组的OS显著改善(中位数,46.4个月vs. 20.9个月;P = 0.02)。dCRT + cICIs组的PFS优于dCRT组(中位数,27.4 vs 12.9个月;P = 0.02)。sIPTW后,dCRT + cICIs组的OS在数值上优于dCRT组(中位数,42.9 vs. 21.6个月;P = 0.1), 1年和2年OS率均有所改善。dCRT + cICIs组和dCRT组的PFS无显著差异(中位数分别为23.0个月和13.0个月;P = 0.2), dCRT + cICIs组的1年和2年PFS在数值上更好。在dCRT + cICIs组中,大约43.4%的患者经历了irae, 13.2%的患者发生了3-4级irae。最常见的是甲状腺功能减退,占11.3%。结论:我们的初步研究结果表明,dCRT后的巩固免疫治疗可能会延长LA-ESCC患者的OS和PFS,并且irae通常是耐受的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
8.40
自引率
3.60%
发文量
935
审稿时长
53 days
期刊介绍: International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome. The subject material appropriate for submission includes: • Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders. • Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state. • Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses. • Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action. • Agents that activate genes or modify transcription and translation within the immune response. • Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active. • Production, function and regulation of cytokines and their receptors. • Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书